Alembic Pharma Gets USFDA Nod For Sumatriptan Injection, Expands U.S. Portfolio

Regulatory Milestone Enhances Alembic’s U.S. Market Offerings

Alembic Pharmaceuticals Ltd has announced that it has secured final approval from the USFDA for its Abbreviated New Drug Application (ANDA) for Sumatriptan Injection USP, 6 mg/0.5 mL, a therapeutic equivalent of Imitrex Injection by GlaxoSmithKline. The drug is indicated for the acute treatment of migraine attacks with or without aura and cluster headaches in adults.

The approval allows Alembic to market the product in the U.S., a key growth geography for the company. According to IQVIA data, the U.S. market for Sumatriptan Injection was estimated at over USD 21 million for the 12 months ending September 2025.

This development is part of Alembic’s broader strategy to strengthen its injectable offerings and deepen its footprint in the U.S. generics market, where it has consistently expanded its pipeline through regulatory clearances.

Key Highlights  

• USFDA grants final approval for Sumatriptan Injection USP  
• Generic equivalent of Imitrex Injection by GSK  
• Indicated for acute migraine and cluster headaches  
• U.S. market size estimated at over USD 21 million  
• Boosts Alembic’s injectable portfolio and U.S. presence  

Sources: Alembic Pharmaceuticals Ltd Exchange Filing, USFDA Database, IQVIA, Business Standard, Economic Times